Furthermore, spiroepoxide or spiroepoxide plus A33+ Li-EV treatment did not affect TGF-β1 levels in colon tissues of IBD mice (Supplementary Fig. 5b). This evidence concerns the gene TGFB1 and inflammatory bowel disease.